TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9555126
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (sulfasalazine, prednisolone, and methotrexate)
Study: 7894897
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of herpetic keratitis
Study: 2974630
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin (SCT) 100 IU, administered four times a week for 8 weeks
Study: 2974630
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 ml saline), administered four times a week for 8 weeks
Study: 31881621
Drug: Hydrocodone/Acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/Acetaminophen
Study: 29584496
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Alprazolam and Hydrocodone/Acetaminophen
Study: 21487150
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of vitamin C daily during training
Study: 19735378
Drug: Immediate HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate HRT (tibolone 2.5 mg)
Study: 19735378
Drug: Delayed HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed HRT (tibolone 2.5 mg)
Study: 17023156
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of dacarbazine monotherapy followed by the same 4-drug regimen of chemoimmunotherapy (arm B)
Study: 11004846
Drug: bFGF in
Normalized name: bFGF
DrugBank: Basic Fibroblast Growth Factor (DB14131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF in BAL from s.A (1.79 pg/ml) and s.B (1.48 pg/ml) in sarcoidosis patients
Study: 11004846
Drug: VEGF in
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VEGF in BAL from s.A (107.5 pg/ml) and s.B (109.7 pg/ml) in sarcoidosis patients
Study: 9133694
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 131I treatment and early thyroxine
Study: 4024920
Drug: Balanced glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced glucose infusion
Study: 29903785
Drug: Internet-mediated cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-mediated cognitive behavioural therapy (ICBT)
Study: 11572225
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy
Study: 23872720
Drug: Intravenous sivelestat,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sivelestat, n = 8
Study: 23872720
Drug: Intravenous saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline, n = 8
Study: 23043036
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin
Study: 14743227
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg atorvastatin
Study: 12398965
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg twice daily)
Study: 1915427
Drug: Pimobendan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan (5 mg twice daily)
Study: 31433355
Drug: E2 vaginal
Normalized name: Prostin E2 Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 vaginal inserts (4, 10, or 25?g)
Study: 27237772
Drug: Uphill treadmill
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uphill treadmill training for 30 minutes daily for 6 weeks
Study: 25866811
Drug: Ursolic acid
Normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursolic acid liposome (UAL) at 56 mg/m2
Study: 25866811
Drug: Ursolic acid
Normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursolic acid liposome (UAL) at 74 mg/m2
Study: 25866811
Drug: Ursolic acid
Normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursolic acid liposome (UAL) at 98 mg/m2
Study: 25866811
Drug: Ursolic acid
Normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursolic acid liposome (UAL) at 74 mg/m2 for pharmacokinetics
Study: 18318569
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg once daily for 5 days
Study: 19419343
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg once daily on day 1 and 250 mg once daily on days 2 through 5
Study: 14759955
Drug: Web intervention
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Web intervention group with continuous access to a bioterrorism educational Web site and weekly exposure to case scenarios.
Study: 30390870
Drug: Milk-honey mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-honey mixture (twice a day for three days)
Study: 27166794
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of folic acid daily (Group 1)
Study: 27166794
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of folic acid daily (Group 2)
Study: 25594129
Drug: Combination blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination blue light therapy (n = 26)
Study: 23870722
Drug: 1.2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g/day n-3 PUFAs
Study: 21691804
Drug: TNF‐α blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α blockers (Infliximab and Adalimumab)
Study: 21691804
Drug: TNF‐α blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α blockers
Study: 21691804
Drug: Control (Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Placebo or other drugs)
Study: 18378871
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of angina and major depression, not using diuretics
Study: 16113850
Drug: Symptomatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic drugs (dipirone or diazepan)
Study: 16113850
Drug: Anti-hypertensive drug
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive drug (captopril)
Study: 12944062
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (historical controls)
Study: 8815681
Drug: Polyclonal immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyclonal immunoglobulin administration
Study: 8815681
Drug: Monoclonal anti‐CMV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal anti‐CMV antibodies (MSL‐109)
Study: 1612492
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (5 mg four times daily)
Study: 6430142
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium citrate (1.3 meq/kg body weight daily for 8 weeks)
Study: 6430142
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (for 8 weeks)
Study: 6430142
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium citrate
Study: 6430142
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium citrate and acetate dialysate
Study: 28744993
Drug: Machined implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machined implants in smokers
Study: 26065445
Drug: Metronidazole 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 1,000 mg (single oral dose)
Study: 20037644
Drug: FP9-TRAP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP9-TRAP vaccine
Study: 20037644
Drug: MVA-TRAP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-TRAP vaccine
Study: 20037644
Drug: FFM ME-TRAP
Normalized name: Trapa bicornis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFM ME-TRAP vaccine
Study: 16773437
Drug: Paclitaxel (175,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175, 210, and 250 mg/m² over 3 h every 3 weeks)
Study: 12842680
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia of proparacaine 0.5% without i.v. cannula
Study: 11085807
Drug: 10,640 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,640 IU 25-HCC per week + 1 g calcium per day
Study: 2876183
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g calcium per day
Study: 1615177
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone diproprionate (1500 micrograms day‐1)
Study: 6377865
Drug: Propranolol b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol b.i.d. (80, 160, 320 mg/day)
Study: 6377865
Drug: Propranolol q.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol q.i.d. (80, 160, 320 mg/day)
Study: 6377865
Drug: Propranolol q.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol q.d. (80, 160, 320 mg/day)
Study: 30360658
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (250 μg daily)
Study: 30027756
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions over 10 weeks)
Study: 23182608
Drug: Remifentanil 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.75 μg/kg
Study: 27687441
Drug: Remifentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.5 μg/kg
Study: 23182608
Drug: Remifentanil 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.25 μg/kg
Study: 24488793
Drug: Standardized postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized postoperative treatment plan alone (no preoperative cryotherapy)
Study: 20070143
Drug: Famciclovir 1000
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Famciclovir 1000 mg twice-daily
Study: 31377160
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation Therapy (RT) alone
Study: 12110494
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (1000 mg/m2) on day 1 preceding cisplatin infusion, 30 mg/m2/24 h cisplatin intravenous bolus days 1-4, and 1000 mg/m2/24 h 5-FU in a 4-h infusion on days 1-4.
Study: 12110494
Drug: Cisplatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (30 mg/m2/24 h) and 5-FU in the same dosage and schedule as in arm A.
Study: 8524975
Drug: m‐chlorophenylpiperazine (m‐CPP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: m‐chlorophenylpiperazine (m‐CPP, 0.08 mg/kg IV) with scopolamine (0.4 mg IV)
Study: 8524975
Drug: scopolamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine (0.4 mg IV)
Study: 8524975
Drug: ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (0.15 mg/kg IV)
Study: 8524975
Drug: scopolamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine (0.4 mg IV) + ondansetron (0.15 mg/kg IV)
Study: 27018419
Drug: Triazolam 0.5
Normalized name: triazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.5 mg
Study: 6128231
Drug: Flunitrazepam 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.5 mg
Study: 6101959
Drug: Flunitrazepam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.25 mg
Study: 21539759
Drug: Nalbuphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (10 mg/1 ml)
Study: 12382386
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1 ml)
Study: 19438689
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ablative fractional laser resurfacing and nonablative laser resurfacing
Study: 17084249
Drug: Torcetrapib 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib 10, 30, 60, or 90 mg/day
Study: 19029469
Drug: Torcetrapib plus
Normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib plus atorvastatin
Study: 7569283
Drug: Mesoglycan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan 100 mg
Study: 7569283
Drug: Mesoglycan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesoglycan 50 mg
Study: 7002481
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection with placebo
Study: 7002481
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection with active tolmetin sodium
Study: 24284101
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid (ALA), 1.0 g, orally administered
Study: 18714218
Drug: Caffeine-containing supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing supplement (SUPP) - 201 mg of caffeine
Study: 16353199
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1500 mg 3 times daily) plus vitamin D(3) 400 IU
Study: 14723480
Drug: Concurrent smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent smoking cessation treatment offered during intensive rehabilitation for alcohol dependence.
Study: 14723480
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment offered six months following intensive rehabilitation for alcohol dependence.
Study: 15964160
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg
Study: 15106359
Drug: Tibolone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 1.25 mg
Study: 11991445
Drug: E2/NETA (estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (estradiol 2 mg plus norethindrone acetate 1 mg)
Study: 9806503
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy (ChT) followed by standard radiation therapy (RT) (60 Gy in 6 weeks)
Study: 9806503
Drug: Combined sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sequential and concurrent ChT and standard RT (60 Gy in 6 weeks)
Study: 9806503
Drug: Sequential ChT
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ChT followed by standard RT (60 Gy in 6 weeks)
Study: 28435128
Drug: Fast-track protocol
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-track protocol (no preoperative bowel preparation, early restoration of diet, no postoperative antibiotics, early postoperative mobilization)
Study: 24354899
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin pump training
Study: 20199764
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV-7)
Study: 17112807
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg/d for 8 days)
Study: 15098972
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide 0.01% in combination with tretinoin and hydroquinone
Study: 15098972
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone as monotherapy
Study: 20525031
Drug: Behavioral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatments for co-occurring SUD and PTSD (specifics not provided)
Study: 15972378
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (platinum-based regimens)
Study: 15972378
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (specific regimens not detailed)
Study: 12004845
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no adjuvant chemotherapy)
Study: 10505538
Drug: Medium-dose hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose hirudin
Study: 10505538
Drug: Low-dose hirudin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hirudin
Study: 10505538
Drug: Moderate-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity warfarin (INR 2-2.5)
Study: 27112607
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use
Study: 29923073
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) treatment
Study: 29923073
Drug: PRP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP treatment
Study: 3168311
Drug: Methimazole (MMI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole (MMI, 40 mg/day)
Study: 3168311
Drug: Methimazole +
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole + Sodium Ipodate (MMI + Na Ipodate, 1 g/day)
Study: 3168311
Drug: Methimazole +
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole + Saturated Solution of Potassium Iodide (MMI + SSKI, 6 drops twice daily)
Study: 28338191
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray 10 g/100 ml at 5 min before intercourse (G1)
Study: 28338191
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once daily (G2)
Study: 28338191
Drug: Tadalafil once
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil once daily plus lidocaine spray before planned sexual activity (G3)
Study: 19273708
Drug: Edrecolomab (ED)
Normalized name: edrecolomab
DrugBank: Edrecolomab (DB13375)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrecolomab (ED) plus fluorouracil (FU) based therapy
Study: 19273708
Drug: Fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FU) based therapy alone
Study: 17363845
Drug: rosuvastatin 5-40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 5-40 mg
Study: 17363845
Drug: rosuvastatin <
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin < or = 20 mg
Study: 17363845
Drug: rosuvastatin <
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin < or = 40 mg
Study: 15543084
Drug: 0.4% copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% copper oxide ointment
Study: 15543084
Drug: 20% elementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% elementary copper ointment
Study: 9647551
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 25 mg/day plus testosterone enanthate (TE) 100 mg/week
Study: 9647551
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 12.5 mg/day plus testosterone enanthate (TE) 100 mg/week
Study: 8086694
Drug: Oral IgA‐IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral IgA‐IgG
Study: 8086694
Drug: Oral Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Gentamicin
Study: 2722974
Drug: Brand A
Normalized name: Select Brand Aspirin 325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand A ranitidine tablets
Study: 2722974
Drug: Brand B
Normalized name: Select Brand Bulk-Forming Laxative Powder for Suspension (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand B ranitidine tablets
Study: 9292
Drug: Alprenolol 600
Normalized name: alprenolol
DrugBank: Alprenolol (DB00866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol 600 mg daily in divided doses for six weeks
Study: 9292
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy for six weeks
Study: 31549424
Drug: All-on-4 rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All-on-4 rehabilitation in the maxilla using at least two Zygoma implants (group 2)
Study: 25656375
Drug: Group M+R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group M+R (5ml solution containing 0.25% ropivacaine plus 5mg/kg magnesium sulphate)
Study: 25656375
Drug: Group M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group M (5ml solution containing 5mg/kg magnesium sulphate)
Study: 21556447
Drug: Intramuscular methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular methyl prednisolone (40 mg) administered at two-week intervals, starting at the time of the procedure.
Study: 11703562
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg melatonin at 18:00 hr
Study: 11703562
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg melatonin at 20:00 hr
Study: 11703562
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg melatonin at 21:00 hr
Study: 10423639
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg melatonin
Study: 9502357
Drug: Structured exercise
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured exercise prescription